Titre
Systematic analysis of factors associated with progression and regression of ulcerative colitis in 918 patients.
Type
article
Institution
UNIL/CHUV/Unisanté + institutions partenaires
Périodique
Auteur(s)
Safroneeva, E.
Auteure/Auteur
Vavricka, S.
Auteure/Auteur
Fournier, N.
Auteure/Auteur
Seibold, F.
Auteure/Auteur
Mottet, C.
Auteure/Auteur
Nydegger, A.
Auteure/Auteur
Ezri, J.
Auteure/Auteur
Straumann, A.
Auteure/Auteur
Rogler, G.
Auteure/Auteur
Schoepfer, A.M.
Auteure/Auteur
Contributrices/contributeurs
Bauerfeind, P.
Beglinger, C.
Begré, S.
Bengoa, J.
Binek, J.
Boller, D.
Borovicka, J.
Braegger, C.
Burnand, B.
Camara, R.
Criblez, D.
de Saussure, P.
Degen, L.
Delarive, J.
Ehmann, T.
Engelmann, M.
Wafa, AE.
Felley, C.
Frei, A.
Frei, P.
Frei, R.
Fried, M.
Froehlich, F.
Gallot-Lavallée, S.
Gerlach, T.
Geyer, M.
Girardin, M.
Goetze, O.
Haack, H.
Hediger, S.
Hengstler, P.
Heyland, K.
Janiak, P.
Juillerat, P.
Brondolo, VK.
Knoblauch, C.
Kullak-Ublick, GA.
Maillard, M.
Manser, C.
Marbet, U.
Manz, M.
Meier, R.
Meyenberger, C.
Michetti, P.
Mottet, C.
Müller, C.
Müllhaupt, B.
Nicolet, T.
Nydegger, A.
Piccoli, F.
Pilz, J.
Pittet, V.
Rentsch, R.
Rey, JP.
Rogler, D.
Rogler, G.
Sagmeister, M.
Sauter, B.
Schaub, N.
Schibli, S.
Schoepfer, AM.
Seibold, F.
Spalinger, J.
Stadler, P.
Steuerwald, M.
Straumann, A.
Sulz, M.
Thorens£££Joël£££ J.,
Vader, JP.
Vavricka, SR.
Vögtlin, J.
Von Känel, R.
Wachter, G.
Wermuth, J.
Wiesel, P.
Groupes de travail
Swiss IBD Cohort Study Group
Liens vers les personnes
Liens vers les unités
ISSN
1365-2036
Statut éditorial
Publié
Date de publication
2015
Volume
42
Numéro
5
Première page
540
Dernière page/numéro d’article
548
Peer-reviewed
Oui
Langue
anglais
Notes
Publication types: Journal ArticlePublication Status: ppublish
Résumé
BACKGROUND: Studies that systematically assess change in ulcerative colitis (UC) extent over time in adult patients are scarce.
AIM: To assess changes in disease extent over time and to evaluate clinical parameters associated with this change.
METHODS: Data from the Swiss IBD cohort study were analysed. We used logistic regression modelling to identify factors associated with a change in disease extent.
RESULTS: A total of 918 UC patients (45.3% females) were included. At diagnosis, UC patients presented with the following disease extent: proctitis [199 patients (21.7%)], left-sided colitis [338 patients (36.8%)] and extensive colitis/pancolitis [381 (41.5%)]. During a median disease duration of 9 [4-16] years, progression and regression was documented in 145 patients (15.8%) and 149 patients (16.2%) respectively. In addition, 624 patients (68.0%) had a stable disease extent. The following factors were identified to be associated with disease progression: treatment with systemic glucocorticoids [odds ratio (OR) 1.704, P = 0.025] and calcineurin inhibitors (OR: 2.716, P = 0.005). No specific factors were found to be associated with disease regression.
CONCLUSIONS: Over a median disease duration of 9 [4-16] years, about two-thirds of UC patients maintained the initial disease extent; the remaining one-third had experienced either progression or regression of the disease extent.
AIM: To assess changes in disease extent over time and to evaluate clinical parameters associated with this change.
METHODS: Data from the Swiss IBD cohort study were analysed. We used logistic regression modelling to identify factors associated with a change in disease extent.
RESULTS: A total of 918 UC patients (45.3% females) were included. At diagnosis, UC patients presented with the following disease extent: proctitis [199 patients (21.7%)], left-sided colitis [338 patients (36.8%)] and extensive colitis/pancolitis [381 (41.5%)]. During a median disease duration of 9 [4-16] years, progression and regression was documented in 145 patients (15.8%) and 149 patients (16.2%) respectively. In addition, 624 patients (68.0%) had a stable disease extent. The following factors were identified to be associated with disease progression: treatment with systemic glucocorticoids [odds ratio (OR) 1.704, P = 0.025] and calcineurin inhibitors (OR: 2.716, P = 0.005). No specific factors were found to be associated with disease regression.
CONCLUSIONS: Over a median disease duration of 9 [4-16] years, about two-thirds of UC patients maintained the initial disease extent; the remaining one-third had experienced either progression or regression of the disease extent.
PID Serval
serval:BIB_0E0E478D9B11
PMID
Open Access
Oui
Date de création
2015-07-28T13:49:02.407Z
Date de création dans IRIS
2025-05-20T16:15:29Z